Ironwood Pharmaceuticals | IRWD - Current Liabilities


Ironwood Pharmaceuticals reported $236.31M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Almirall EUR 350.64M 52.12M Dec/2025
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Astellas Pharma JPY 1.22T 106.19B Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Charles River Laboratories USD 1.09B 26.61M Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Esperion Therapeutics USD 300.36M 451K Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
Pacira USD 108.79M 11.8M Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Takeda JPY 2.43T 180.65B Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025